Latest Articles
-
Merger And Acquisition Watch Solta Medical Will Be Acquired Soon Here Is Why
Submitted by Scott Matusow as part of our contributors program . In August of 2012, I wrote an article detailing why Obagi Medical Products would be acquired soon. Obagi was under pressure from Voce Capital Management to sell the company. Obag...
-
A Look At Merck’s Anti-Infectives Division
Anti-infective drugs form one of the biggest business segments for Merck (NYSE:MRK) accounting for about 25% of its value according to our estimates. These drugs are designed and developed to counteract infections and include anti-septics, disinf...
-
Billion Fund Manager James Barrow And His Latest Dividend Stock Buys
Submitted by Dividend Yield as part of our contributors program . James Barrow’s latest dividend stock buys and his portfolio originally published at long-term-investments.blogspot.com . James Barrow is a relatively unknown fund managers...
-
Seven Biotech Options That Buck Tradition: Christian Glennie
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (6/6/13) Edison Investment Research assesses the value of emerging companies with a model ...
-
Merck’s Shares Perk Up On Cancer Drug Clinical Trial Data
Like other major pharmaceutical companies, Merck (NYSE:MRK) is battling against the impact of patent expiries for several of its major drugs including Singulair, Propecia, Clarinex, Maxalt, Cozaar and Hyzaar. Out of these, the impact on asthma d...
-
13 Highly Shorted Healthcare Dividend Stocks
Submitted by Dividend Yield as part of our contributors program . 13 Highly Shorted Healthcare Dividend Stocks Healthcare dividend stocks with the highest float short ratio originally published at “ long-term-investments.blogspot.com &...
-
Investing in Cancer Research Is Worth the Risk: Echo He
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (5/23/13) If investigators could find a way to make breast cancer survivors truly cancer f...
-
Why Dow Jones Laggards Are Important Leading Indicators
Submitted by Abby Joseph at Profit Confidential as part of our contributors program . There very well could be more upside in the Dow Jones Industrial Average. Many components have been underperforming the stock market significantly; if there i...
-
Can Merck’s Pipeline Offset The Pain From Major Patent Expirations?
The pressure on Merck ‘s (NYSE:MRK) revenue growth is likely to continue in 2013, as the company battles multiple patent expiries and unfavorable currency movements. It is likely that there will be no respite in the near term, although the ...
-
Quickly Approaching Biopharma Catalyst Events
Submitted by Scott Matusow as part of our contributors program . Quickly Approaching Biopharma Catalyst Events Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching...
-
AVEO Poised To Move Higher Before May 2 FDA Adcomm Catalyst, Obama Care, And Platform Potential
Submitted by Scott Matusow as part of our contributors program . The advent of The Affordable Care act (Obama Care) on the horizon as the healthcare sector of the market continues its strong rally. With new Food and Drug Administration (FDA) r...
-
6 Biotechs With Staggering Potential: Zacks Analyst Grant Zeng
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (4/4/13) When it comes to picking biotech stocks, does a buyside perspective matter more t...
-
7 Big Growth Stories in Biotech: Keith Markey
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (3/28/13) As a former biotechnology researcher and 25-year Wall Street veteran, Griffin Se...
-
The Stem Cell Revolution Can Jump-Start Your Portfolio: Jason Kolbert
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (3/14/13) No single solution will emerge from the growing realm of stem cell technology an...
-
Merck Jumps As IMPROVE-IT Study Will Continue
Merck ‘s (NYSE:MRK) stock jumped Tuesday as investors cheered the Data Safety Monitoring Board’s recommendation that the “IMPROVE-IT” trial, which is being conducted to prove the efficacy and safety of Merck’s blockb...
